November 2014 For latest updates Register today Home About PCSK9 Forum News Expert Opinion Education & Resources Register PCSK9 Education and Research Forum: November 2014 New on PCSK9 Education and Research Forum Focus on FH Highlights from the 2014 FH Global Summit in association with the FH Foundation The FH Global Summit offers a unique opportunity for healthcare workers, policy makers and patient advocacy groups to work together to catalyse progress in FH care. • Highlights Report • Overturning the 1% worldwide detection rate for FH: News on CASCADE FH • Mind the Gap: FAMCHOL and I FIGHT • Not only lower BUT but SOONER is better • Is there a need for a unified definition for FH? Other FH News RUTHERFORD-2 in heterozygous FH, TESLA in homozygous FH: What are the implications for PCSK9-targeted therapy? Comment from Professors Raul Santos, Brazil and Gerald Watts, Australia From the Editors Heterogeneity in FH: What are the implications for management? Prof Derick Raal, University of the Witwatersrand, South Africa Review VIDEO: Why is it critical to target children with FH? Dr Albert Wiegman, Academic Medical Center, Amsterdam, the Netherlands VIDEO: Unmet needs in children with FH Dr Sam Gidding, Nemours Biomedical Research, Wilmington, Delaware SLIDES: How to recognise FH? Prof Eric Bruckert, Pitié-Salpêtrière Hospital, Paris, France New Trials VIDEO: The 10 countries FH Project Prof Gerald Watts Send an invitation to join PCSK9 Forum to your colleagues, click here for the invite linkOur mission Our goal PCSK9 Education and Research Forum is the major, globally-recognised resource of independent knowledge of PCSK9 science and its translation to therapeutic innovation. Our mission is to facilitate development of these new treatments in order to transform the prognosis of millions of people with hypercholesterolaemia and accelerated atherosclerotic vascular disease. Our response to this challenge Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target. Our partnership and outreach Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes.   About PCSK9 Education and Research Forum • Watch the Aims & Objectives video • Read our Mission Statement • Partnership and outreach • Meet our Editorial Board • View Forthcoming Meetings News • Dr Albert Wiegman, the Netherlands: Why is it critical to target children with FH? • Prof Gerald Watts, Australia: Discusses the 10 countries project in FH • PCSK9 inhibition: lipid-modifying benefits beyond LDL-C lowering • PCSK9 variants associated with cerebral ischaemic stroke in Han Chinese • R46L variant: an important modifier of the FH Read more news » Tweets @PCSK9Forum Video: Prof Gerald Watts, Australia: Discusses the 10 countries project in FH http://www.pcsk9forum.org/ prof-gerald-watts-australia-discusses -the-10-countries-project-in-fh/ … Dr Albert Wiegman, the Netherlands: Why is it critical to target children with FH? http://www.pcsk9forum.org/ dr-albert-wiegman-the-netherlands-why-is-it-critical-to-target-children-with-fh/ … Heterogeneity in #FH: What are the implications for management? http://www.pcsk9forum.org/heterogeneity-in-fh-what-are-the-implications-for-management/ … Very low #LDLcholesterol and risk for #haemorrhagiccomplications after #ischaemicstroke: should we be worried with #PCSK9targeted therapy #PCSK9 loss of function mutations - do they have direct effects on #atherogenesis? Tomorrow is National FH Awareness Day @TheFHFoundation #knowFH http://thefhfoundation.org/fh-awareness-day/ … Why new NLA guidelines for dyslipidaemia? A view from the authors by Prof Matthew Ito http://www.pcsk9forum.org/ why-new-nla-guidelines-for-dyslipidaemia-a-view-from-the-authors/ … Hot off the Press: US NLA releases new recommendations for management of dyslipidemia https://www.lipid.org/ recommendations/conclusions …   Supported by educational grants from:   Copyright PCSK9 Forum 2014. Please click here to unsubscribe from future mailings.